ANDA 213630, held by Hikma Pharmaceuticals. Prochlorperazine Edisylate.
As of Nov 19, 2026, ANDA 213630 (Prochlorperazine Edisylate), held by Hikma Pharmaceuticals, was first approved by FDA on Nov 22, 2022, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 22, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prochlorperazine EdisylateEQ 5MG BASE/ML · injectable;injection | Prochlorperazine Edisylate | Discontinued |
| Feb 19, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 7, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 22, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters